Floatz logo

Solriamfetol

Hypersomnia

Duke UniversitySmall moleculePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hypersomnia cohort.

Asset / SponsorPhaseRating
CAFFEINE
Ron Postuma
Phase 2/3B
Modafinil
Duke University
Phase 2B
MELATONIN
Duke University
Phase 2B
Valiloxybate
XWPharma
Phase 2CCC
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT
Brigham and Women's Hospital
Early Phase 1C
Gate-101
Syndeio Biosciences, Inc
Phase 1NR

Same molecule, other indications

Solriamfetol is also rated in:

long COVID-19Dormant
B
Indicative ·
62 / 100
View asset →
sleep disorderDormant
B
Indicative ·
57 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →